SCARB1

Across TCGA pan-cancer cohorts, SCARB1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SCARB1 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SCARB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SCARB1 expression acts as an unfavorable survival marker.

STAD, SARC, and CESC are the cancer types where SCARB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	24	view →
SARC	OS	Median	All	0.032	0.861	<.001	12	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	12	view →
PCPG	DFS	Median	All	0.112	0.769	.021	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SCARB1–STAD (OS)

Open the STAD breakdown →